Sign in →

TEST ID THYRO Thyrotropin Receptor Antibody, Serum

Reporting Name

Thyrotropin Receptor Ab, S

Specimen Type

Serum


Specimen Required


Patient Preparation:

1. For 12 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.

2. Patient should not be receiving heparin treatment.

Collection Container/Tube:

Preferred:  Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Specimen Minimum Volume

0.75 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days

Method Name

Electrochemiluminescence Immunoassay

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus Reject

Reference Values

≤1.75 IU/L

Day(s) Performed

Monday through Saturday

Report Available

1 to 3 days

Specimen Retention Time

2 weeks

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

83520

Forms

If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.

Useful For

Recommended first-line test for detection of thyrotropin receptor antibodies

 

The following situations:

-Differential diagnosis of etiology of thyrotoxicosis in patients with ambiguous clinical findings and/or contraindicated (eg, pregnant or breast-feeding) or nondiagnostic thyroid radioisotope scans

-Diagnosing clinically suspected Graves disease (GD) (eg, extrathyroidal manifestation of GD include endocrine exophthalmos, pretibial myxedema, thyroid acropachy) in patients with normal thyroid function tests

-Determining the risk of neonatal thyrotoxicosis in a fetus of a pregnant female with active or past active GD

-Differential diagnosis of gestational thyrotoxicosis versus first trimester manifestation or recurrence of GD

-Assessing the risk of GD relapse after antithyroid drug treatment